Document Detail


Challenges for the Development of New Treatments for Severe Asthma: A Pharmaceutical Perspective.
MedLine Citation:
PMID:  21406057     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
The pharmaceutical industry is interested in developing new treatments for severe asthma (SA), recognising that there is a substantial unmet clinical need in this area. However, it faces a significant set of barriers in attempting to do so, including a) problems arising from the way SA is defined, b) the heterogeneity of this condition, c) poor understanding of its aetiology, d) the absence of validated animal and tissue or cellular models, e) the need for biomarkers and experimental clinical models of severe asthma and its sub-groups, and f) the length and size of the clinical trials likely to be required to obtain approval and reimbursement. The discovery and validation of novel biomarkers and surrogates is likely to be a crucial part of meeting these challenges, and many academic groups and pharmaceutical companies working in this area are increasingly turning to pre-competitive, highly collaborative ways of working to address them.
Authors:
Richard G Knowles
Related Documents :
9711327 - Allometry of ecg waves in mammals.
7705077 - An algorithm to detect low incidence arrhythmic events in electrocardiographic records ...
23552247 - Assessing the efficiency of different cso positions based on network graph characterist...
24403397 - Biased predecisional processing of leading and nonleading alternatives.
25168757 - Neuroendocrine control of seasonal plasticity in the auditory and vocal systems of fish.
23095817 - A study on optimizing the cryopreservation methods for bama miniature pig semen.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2011-3-15
Journal Detail:
Title:  Current pharmaceutical design     Volume:  -     ISSN:  1873-4286     ISO Abbreviation:  -     Publication Date:  2011 Mar 
Date Detail:
Created Date:  2011-3-16     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9602487     Medline TA:  Curr Pharm Des     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
Director, Refractory Respiratory Inflammation Biology, Respiratory Centre of Excellence for Drug Discovery, GlaxoSmithKline R & D, Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK. richard.g.knowles@gsk.com.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Targeting HIV: past, present and future.
Next Document:  Challeges in the Management of Severe Asthma: Role of Current and Future Therapies.